Thomas G. Ricks
Thomas G. Ricks's purchase track record
Thomas G. Ricks has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/9/2021 | FTH | $250K | -52.4% | -69.8% | -13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
Transaction History
| OVV | ▲ Buy | Option Exercise | 3,510 | — | 5/21/2026 | View on chart |
| OVV | ▼ Sell | Gift | 900 | $0 | 12/5/2025 | View on chart |
| OVV | ▼ Sell | Gift | 900 | $0 | 12/5/2025 | View on chart |
| OVV | ▼ Sell | Gift | 900 | $0 | 12/5/2025 | View on chart |
| OVV | ▼ Sell | Gift | 900 | $0 | 12/5/2025 | View on chart |
| OVV | ▲ Buy | Option Exercise | 5,501 | — | 5/16/2025 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,213 | — | 5/17/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 8,402 | — | 3/8/2024 | View on chart |
| FTH | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 | View on chart |
| OVV | ▲ Buy | Option Exercise | 6,074 | — | 5/18/2023 | View on chart |
| OVV | ▲ Buy | Option Exercise | 14,709 | — | 3/8/2023 | View on chart |
| FTH | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 19,231 | $1.1M | 6/7/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 10,000 | $500K | 5/23/2022 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,499 | — | 5/18/2022 | View on chart |
| OVV | ▼ Sell | Open Market | 10,000 | $537K | 4/18/2022 | View on chart |
| OVV | ▲ Buy | Open Market | 19 | — | 3/31/2022 | View on chart |
| OVV | ▲ Buy | Option Exercise | 5,184 | — | 3/8/2022 | View on chart |
| FTH | ▲ Buy | Open Market | 20,000 | $117K | 12/10/2021 | View on chart |
| FTH | ▲ Buy | Open Market | 20,000 | $132K | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ovintiv receives multiple analyst price target raises
Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.
Ovintiv receives multiple analyst price target raises. Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.